The use of cancer-related therapies in cancer patients hospitalized at the end of life has increased in many countries over time. Given the scarcity of published Swiss data, the objective of this study was to evaluate the influence of hospital type and other factors on the delivery of health care during the last month before death. Claims data were used to assess health care utilization of cancer patients (identified by cancer registry data of four participating Swiss cantons) who deceased between 2006 and 2008. Primary endpoints were delivery of cancer-related therapies during the last 30 days before death. Multivariate logistic regression assessed the explanatory value of hospital type, patient and geographic characteristics. Of 3,809 identified cancer patients in the claims database, 2,086 patients dying from cancer were hospitalized during the last 30 days before death, generating 2,262 inpatient episodes. Anticancer drug therapy was given in 22.2% and radiotherapy in 11.7% of episodes. Besides age and cancer type, the canton of residence and hospital type showed independent, statistically significant associations with intensity of care, which was highest in university hospitals. These results should initiate a discussion among oncologists in Switzerland and may question the compliance with standard of care guidelines for terminal cancer patients. i 2014 S. Karger AG, Basel

Keywords:
End of life, Cancer, Radiotherapy, Chemotherapy, Health insurance, Hospitalization
1.
Earle CC, Landrum MB, Souza JM, et al: Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;26:3860-3866.
2.
Meeussen K, Van den Block L, Echteld MA, et al: End-of-life care and circumstances of death in patients dying as a result of cancer in Belgium and the Netherlands: a retrospective comparative study. J Clin Oncol 2011;29:4327-4334.
3.
Toole M, Lutz S, Johnstone PA: Radiation oncology quality: aggressiveness of cancer care near the end of life. J Am Coll Radiol 2012;9:199-202.
4.
Guadagnolo BA, Liao KP, Elting L, et al: Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol 2013;31:80-87.
5.
Pardon K, Chambaere K, Pasman HR, et al: Trends in end-of-life decision making in patients with and without cancer. J Clin Oncol 2013;31:1450-1457.
6.
Earle CC: Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2003;22:315-321.
7.
Earle CC: Patterns of care studies: creating ‘an environment of watchful concern'. J Clin Oncol 2003;21:4479-4480.
8.
Harrington SE, Smith TJ: The role of chemotherapy at the end of life: ‘when is enough, enough?'. JAMA 2008;299:2667-2678.
9.
Grunfeld E, Lethbridge L, Dewar R, et al: Towards using administrative databases to measure population-based indicators of quality of end-of-life care: testing the methodology. Palliat Med 2006;20:769-777.
10.
Grunfeld E, Urquhart R, Mykhalovskiy E, et al: Toward population-based indicators of quality end-of-life care: testing stakeholder agreement. Cancer 2008;112:2301-2308.
11.
Ho TH, Barbera L, Saskin R, et al: Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol 2011;29:1587-1591.
12.
Shugarman LR, Bird CE, Schuster CR, Lynn J: Age and gender differences in medicare expenditures and service utilization at the end of life for lung cancer decedents. Womens Health Issues 2008;18:199-209.
13.
Smith AK, Earle CC, McCarthy EP: Racial and ethnic differences in end-of-life care in fee-for-service Medicare beneficiaries with advanced cancer. J Am Geriatr Soc 2009;57:153-158.
14.
Matter-Walstra KM, Achermann R, Rapold R, et al: Delivery of health care at the end of life in cancer patients of four Swiss cantons: a retrospective database study (SAKK 89/09). BMC Cancer 2014;14:306-317.
16.
Jamrozik J, Bohmanova J, Schaeffer LR: Selection of locations of knots for linear splines in random regression test-day models. J Anim Breed Genet 2010;127:87-92.
17.
Smith PL: Splines as a useful and convenient statistical tool. Am Stat 1979;33:57-62.
18.
Emanuel EJ, Young-Xu Y, Levinsky NG, et al: Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 2003;138:639-643.
19.
Earle CC, Neville BA, Landrum MB, et al: Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004;22:315-321.
20.
Seow H, Barbera L, Sutradhar R, et al: Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 2011;29:1151-1158.
21.
Keating NL, Landrum MB, Lamont EB, et al: End-of-life care for older cancer patients in the Veterans Health Administration versus the private sector. Cancer 2010;116:3732-3739.
22.
Morishima T, Lee J, Otsubo T, et al: Impact of hospital case volume on quality of end-of-life care in terminal cancer patients. J Palliat Med 2013;16:173-178.
23.
Sacerdote C, Baldi I, Bertetto O, et al: Hospital factors and patient characteristics in the treatment of colorectal cancer: a population based study. BMC Public Health 2012;12:775.
24.
Morden NE, Chang CH, Jacobson JO, et al: End-of-life care for Medicare beneficiaries with cancer is highly intensive overall and varies widely. Health Aff (Millwood) 2012;31:786-796.
25.
Sigurdardottir KR, Haugen DF, Bausewein C, et al: A pan-European survey of research in end-of-life cancer care. Support Care Cancer 2012;20:39-48.
26.
Earle CC, Park ER, Lai B, et al: Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol 2003;21:1133-1138.
27.
Lorenz K, Lynn J, Dy S, et al: Cancer care quality measures: symptoms and end-of-life care. Evid Rep Technol Assess (Full Rep) 2006;137:1-77.
28.
Ostgathe C, Voltz R: Quality indicators in end-of-life care. Curr Opin Support Palliat Care 2010;4:170-173.
29.
Seow H, Snyder CF, Mularski RA, et al: A framework for assessing quality indicators for cancer care at the end of life. J Pain Symptom Manage 2009;38:903-912.
30.
Tang ST, Wu SC, Hung YN, et al: Trends in quality of end-of-life care for Taiwanese cancer patients who died in 2000-2006. Ann Oncol 2009;20:343-348.
31.
Gielen B, Remacle A, Mertens R: Patterns of health care use and expenditure during the last 6 months of life in Belgium: differences between age categories in cancer and non-cancer patients. Health Policy 2010;97:53-61.
32.
Tan TS, Jatoi A: End-of-life hospital costs in cancer patients: do advance directives or routes of hospital admission make a difference? Oncology 2011;80:118-122.
33.
Walker H, Anderson M, Farahati F, et al: Resource use and costs of end-of-Life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. J Palliat Care 2011;27:79-88.
34.
Zhang B, Wright AA, Huskamp HA, et al: Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med 2009;169:480-488.
35.
Teno JM, Gozalo PL, Bynum JP, et al: Change in end-of-life care for Medicare beneficiaries: site of death, place of care, and health care transitions in 2000, 2005, and 2009. JAMA 2013;309:470-477.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.